Myocardial remodeling and new therapeutic strategies in chronic heart failure;Rimodellamento miocardico e nuove strategie terapeutiche nella insufficienza cardiaca cronica

Rivista Italiana di Pediatria

Volumn 27, Issue 3, 2001, Pages 311-317

  Distefano, G ^a  

^a UNIVERSITY OF CATANIA   (Italy)

Author keywords

Heart failure; Myocardial remodeling

Indexed keywords

ADENOSINE TRIPHOSPHATE; ALDOSTERONE; ANGIOTENSIN; CAPTOPRIL; ENDOTHELIN; PENTOXIFYLLINE; RENIN; TUMOR NECROSIS FACTOR; UBIQUINONE;

APOPTOSIS; CARDIOMYOPATHY; HEART FAILURE; HEART MUSCLE ISCHEMIA; HEART MUSCLE OXYGEN CONSUMPTION; HEART VENTRICLE REMODELING; INOTROPISM; PATHOPHYSIOLOGY; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SARCOLEMMA; SARCOPLASM; SARCOPLASMIC RETICULUM;

EID: 0034913064     PISSN: 03925161     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (60)

1. Herzinsuffizienz im kindesalter
2. Congestive heart failure in children
3. Myocardial beta-adrenoceptor density and the distribution of beta 1- and beta 2-adrenoceptor subpopulations in children with congenital heart disease
4. Aldosterone and spironolactone in heart failure
5. Maturation of the heart
6. Cardiac calcium release channel (ryanodine receptor) in control and cardiomyopathic human hearts; mRNA and protein contents are differentially regulated
7. On the change of cardiac action potential with age: A study in dogs
8. Structure and function of cardiac sodium and potassium channels
9. Why does the myocardium fail? Insights from basic science
10. Protooncogene induction and reprogramming of cardiac gene expression produced by pressure overload
11. Molecular and cellular mechanism of myocardial failure
12. Autocrine release of angiotensin-II medicates stretch-induced hypertrophy of cardiac myocytes in vitro
13. Endothelin-I is involved in mechanical stress-induced cardiomyocyte hypertrophy
14. 1, expression in rat ventricular myocytes
15. Age-dependent ventricular response to pressure overload. Consideration for the arterial switch operation
16. Defective excitation-contraction coupling in experimental cardiac hypertrophy and heart failure
17. Myosin heavy gene expression in human heart failure
18. Peptide growth factors can provoke «fetal» contractile protein gene expression in rat cardiac myocytes
19. Alterations in sarcoplasmic reticulum gene expression in human heart failure. A possible mechanism for alterations in systolic and diastolic properties of the failing myocardium
20. Regulation of human heart contractility by essential myosin light chain isoforms
21. Troponin T isoform expression in humans: A comparison among normal and failing adult heart, fetal heart, and adult and fetal skeletal muscle
22. Apoptosis in pressure overload-induced heart hypertrophy in the rat
23. Cytoskeletal role in the contractile dysfunction of hypertrophied myocardium
24. Myocardial fibrosis: Its functional significance and regulatory factors
25. Remodelling of the right and left ventricles in experimental hypertension
26. Compensated cardiac hypertrophy: Arrhythmogenicity and the new myocardial phenotype. I. Fibrosis
27. New target for heart-failure therapy: Endothelin, inflammatory cytokines, and oxidative stress
28. Endothelin induction of inositol phospholipid hydrolysis sarcomere assembly, and cardiac gene expression in ventricular myocytes: A paracrine mechanism for myocardial cell hypertrophy
29. Evidence for endothelin-1-mediated vasoconstriction in severe chronic heart failure
30. ECE-1: A membrane-bound metallo-protease that catalyzes the proteolytic activation of big endothelin-1
31. Proinflammatory cytokine levels in patients with depressed left ventricular ejection fraction: A report from the Studies of Left Ventricular Dysfunction (SOLVD)
32. Tumour necrosis factor and inducible nitric oxide synthase in dilated myocardiomiopathy
33. Tumour necrosis factors α-induced apoptosis in cardiac myocytes. Involvement of the sphingolipid signaling cascade in cardiac cell death
34. Interleukin-I β-modulates growth and phenotype neonatal rat cardiac myocytes
35. Interferon-β induces metalloproteinase mRNA expression in human fibroblasts: Role of activators protein-1
36. A phase 1 trial of tumor necrosis factor receptor (p75) fusion protein (TNFR:Fc) in patients with advanced heart failure
37. Randomised investigation of effects of pentoxifylline on left-ventricular performance in idiopathic dilated cardiomyopathy
38. Adenosine inhibits lipopolysaccharide-induced secretion of tumor necrosis factor-α in the failing human heart
39. Stretch-induced programmed myocyte cell death
40. Human fibroblasts release reactive oxygene species in response to interleukin-I or tumour necrosis factor-α
41. Oxy-free radical system in heart failure and therapeutic role of oral vitamin E
42. Effects of coenzyme Q10 therapy in patients with congestive heart failure: A long-term multicenter randomized study
43. Preventing the cardiotoxicity of anthracyclines by dexrazoxane
44. Randomized trial of losartan versus captopril in patients over 65 with heart failure
45. Natriuretic peptides
46. The potential for growth hormone in the management of heart failure
47. Regulation of rat growth hormone receptor gene expression
48. Insuline-like growth factors and insuline increase the contractility of neonatal rat cardiocytes in vitro
49. Clinical aspects of growth deficiency in adults
50. Growth hormone and heart
51. A preliminary study of growth hormone in the treatment of dilated cardiomyopathy
52. Sympathetic deactivation by growth hormone treatment in patients with dilated cardiomyopathy
53. Practical guidelines for initiation of β-adrenergic blockade in patients with chronic heart failure
54. Changes in myocardial gene expression associated with β-blocker-related improvement in ventricular systolic function
55. β-blocker therapy of severe congestive heart failure in infants with left to right shunts
56. β-blocker therapy in an infant with pulmonary hypertension
57. β-blocker treatment of dilated cardiomyopathy with congestive heart failure in children: A multi-institutional experience
58. ++ ATPase activity by calmidazolium
59. Modulation of cytokine production and protection against lethal endotoxemia by the cardiac glycoside ouabain